RE:ZEPATIDE

Description

The image shows a product box and dosage schedule for RE:ZEPATIDE, a tirzepatide product (a dual GLP-1 and GIP receptor agonist) outlined with a 6-week titration table:
• Week 1 & Week 2: Strength 3 mg | Units: 20 units | Volume: 0.2 ml
• Week 3 & Week 4: Strength 4.5 mg | Units: 30 units | Volume: 0.3 ml
• Week 5 & Week 6: Strength 7.5 mg | Units: 50 units | Volume: 0.5 ml
• Administer once weekly

Important Medical & Safety Information

• Visual Description: The image features a dark background with blue and white branding for “RE:ZEPATIDE” alongside a titration chart detailing weekly dosages, units, and injection volumes.
• Unregistered / Compounded Products: Products of this nature often fall under compounded or unregistered peptide categories. In South Africa and many other regions, health authorities (such as SAHPRA) have issued warnings and enforcement actions regarding the safety, sterility, quality control, and lack of regulatory approval for unverified compounded GLP-1/tirzepatide products.
• Potential Side Effects of Tirzepatide:
• Gastrointestinal issues (nausea, vomiting, diarrhea, constipation, abdominal pain)
• Risk of hypoglycemia (low blood sugar), gallbladder problems, or more severe adverse events
• Other systemic or allergic reactions
• Treatment & Guidance Options:
1. Consult a licensed medical doctor or endocrinologist for an official evaluation before starting any metabolic or weight-loss therapy.
2. Transition to officially registered, FDA- or SAHPRA-approved brand-name medications (such as Mounjaro® for tirzepatide) where clinically appropriate.
3. Work with a qualified healthcare provider on a supervised, medically monitored nutrition and lifestyle plan rather than using unverified research or compounded kits.
Make sure to double-check the physical label and consult a qualified healthcare professional to verify proper dosing, reconstitution instructions, and product authenticity.